Form 4: Sarepta Therapeutics EVP Ryan Brown Reports Stock Transactions

EVP and General Counsel of Sarepta Therapeutics, Ryan Brown, reports acquisition and disposal of company stock and stock options.

Summary

• Ryan Brown, EVP and General Counsel of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Brown disposed of 269 shares to cover tax obligations at a price of $126.19 per share.
• Also on March 1, 2024, Brown acquired 6,000 shares of restricted stock units (RSUs) at $0.
• Brown sold 2,000 shares on March 1, 2024, at $125.34 per share to cover taxes related to vesting RSUs.
• Brown was granted 12,500 stock options with an exercise price of $128.67, vesting starting March 1, 2025, and expiring on March 1, 2034.
• Following these transactions, Brown directly owns 31,827 shares of common stock and 12,500 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. The granting of RSUs and stock options is a positive sign, but the sale of shares to cover taxes is a normal occurrence.

Positives

• The granting of 6,000 RSUs and 12,500 stock options to Ryan Brown indicates continued investment in the company's leadership.

Future Outlook

The RSUs vest over four years from the grant date, and the stock options vest monthly starting March 1, 2025, suggesting a long-term incentive structure for the executive.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the biotechnology industry to align management's interests with those of shareholders.
• Vesting schedules for RSUs and stock options typically range from three to five years, which is consistent with Sarepta's four-year vesting schedule.
• Comparing the size of the RSU and option grants to those of executives at similar-sized biotech companies (e.g., BioMarin, Vertex) would provide further context on the competitiveness of Sarepta's compensation practices.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve a relatively small number of shares compared to the company's total outstanding shares.
• The equity grants incentivize the executive to focus on long-term value creation for the company.

Key Dates